Innate Immunity Stimulation Via TLR9 in Early AD
RecruitingNCT05606341Phase: PHASE1Started 2023-03-13
Summary
This single-center, double-blind, placebo-controlled study will recruit in total 39 participants with either Mild Cognitive Impairment due to Alzheimer's disease (MCI) or Mild Alzheimer's disease deme
Eligibility
Sex
ALL
Min Age
60 Years
Max Age
85 Years
Locations
NYU Langone HealthNew York, New York, United States
View full study details on ClinicalTrials.gov
clinicaltrials.gov/study/NCT05606341